Literature DB >> 11330654

Demyelinating disease and hepatitis B vaccination: is there a link?

T Jefferson1, H Heijbel.   

Abstract

The recent decision by the French government to compensate 3 recipients of hepatitis B vaccine preceding the onset of multiple sclerosis presumes a possible causal link and brings into question the use of current rules of causality assessment. Available evidence does not support a causal link or is equivocal but the accuracy of current methods of vaccine surveillance should be urgently improved. Larger and longer randomised trials, updated summaries of evidence, linked databases, prospective vaccination registers, bar-coding of vaccines and standardisation of adverse event definitions are possible measures to address current problems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11330654     DOI: 10.2165/00002018-200124040-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  17 in total

1.  Comparison study of combined DTPw-HB vaccines and separate administration of DTPw and HB vaccines in Thai children.

Authors:  Y Poovorawan; A Theamboonlers; S Sanpavat; V Chongsrisawat; P Willems; A Safary
Journal:  Asian Pac J Allergy Immunol       Date:  1999-06       Impact factor: 2.310

2.  No increase in demyelinating diseases after hepatitis B vaccination.

Authors:  F Zipp; J G Weil; K M Einhäupl
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

3.  Is there a causal link between hepatitis B vaccination and multiple sclerosis?

Authors:  P Monteyne; F E André
Journal:  Vaccine       Date:  2000-04-03       Impact factor: 3.641

4.  Comparison study of the immunogenicity and safety of 5- and 10-microgram dosages of a recombinant hepatitis B vaccine in healthy infants.

Authors:  J Goldfarb; S V Medendorp; H Garcia; K Nagamori; H Rathfon; D Krause
Journal:  Pediatr Infect Dis J       Date:  1996-09       Impact factor: 2.129

5.  School-based hepatitis B vaccination programme and adolescent multiple sclerosis.

Authors:  A D Sadovnick; D W Scheifele
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

6.  [The first episode of central nervous system demyelinization and hepatitis B virus vaccination].

Authors:  E Touzé; O Gout; M H Verdier-Taillefer; O Lyon-Caen; A Alpérovitch
Journal:  Rev Neurol (Paris)       Date:  2000-03       Impact factor: 2.607

7.  Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine.

Authors:  L Herroelen; J de Keyser; G Ebinger
Journal:  Lancet       Date:  1991-11-09       Impact factor: 79.321

8.  Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.

Authors:  G M Schiff; J R Sherwood; J B Zeldis; D S Krause
Journal:  J Adolesc Health       Date:  1995-01       Impact factor: 5.012

9.  The quest for trials on the efficacy of human vaccines. Results of the handsearch of Vaccine.

Authors:  T Jefferson; V Jefferson
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

10.  Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD).

Authors:  M T Niu; P Rhodes; M Salive; T Lively; D M Davis; S Black; H Shinefield; R T Chen; S S Ellenberg
Journal:  J Clin Epidemiol       Date:  1998-06       Impact factor: 6.437

View more
  4 in total

Review 1.  Vaccination against infection in patients with multiple sclerosis.

Authors:  Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

Review 2.  [Vaccination and multiple sclerosis].

Authors:  M Löbermann; A Winkelmann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

Review 3.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Vaccines and multiple sclerosis: a systematic review.

Authors:  Mia Topsøe Mailand; Jette Lautrup Frederiksen
Journal:  J Neurol       Date:  2016-09-07       Impact factor: 6.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.